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Adenoviruses are used extensively as gene transfer
agents, both experimentally and clinically. However,
targeting of liver cells by adenoviruses compromises
their potential efficacy. In cell culture, the adenovirus
serotype 5 fiber protein engages the coxsackievirus
and adenovirus receptor (CAR) tobind cells. Paradox-
ically, following intravasculardelivery,CAR isnotused
for liver transduction, implicating alternate pathways.
Recently, we demonstrated that coagulation factor
(F)X directly binds adenovirus leading to liver infec-
tion. Here, we show that FX binds to the Ad5 hexon,
not fiber, via an interactionbetween theFXGladomain
and hypervariable regions of the hexon surface. Bind-
ing occurs in multiple human adenovirus serotypes.
Liver infection by the FX-Ad5 complex is mediated
throughaheparin-bindingexosite in theFXserinepro-
tease domain. This study reveals an unanticipated
function for hexon in mediating liver gene transfer
in vivo.INTRODUCTION
Adenoviruses are common pathogens used experimentally and
in completed and ongoing clinical trials for gene delivery in on-
cology, cardioangiology, and regenerative medicine and as vac-
cine vectors (Schenk-Braat et al., 2007; Kawabata et al., 2006).Much work has demonstrated the potential benefits and limita-
tions of adenovirus-mediated gene therapy preclinically and clin-
ically, the latter being brought to the forefront by the death of
Jesse Gelsinger in 1999 in response to very high-dose adenovi-
rus type 5 (Ad5) delivered directly into the hepatic artery (Raper
et al., 2003). This dramatically highlighted the need to fully under-
stand the virological and biological aspects that define adenovi-
rus infectivity of liver and toxicity in vivo before vectors could be
fully optimized for clinical use.
Adenoviruses based on human serotype 5 have been studied
extensively, yet fundamental issues relating to infection mecha-
nisms remain to be elucidated, particularly in vivo. Adenoviruses
are principally made up of three major capsid proteins—hexon,
penton, and fiber. The crystal structures of Ad2 and Ad5 hexon
have been solved (Athappilly et al., 1995; Roberts et al., 1986;
Rux and Burnett, 2000) and reveal a complex structure. The
hexon, the major site of antigenicity in adenoviruses (Pichla-
Gollon et al., 2007; Roberts et al., 2006; Sumida et al., 2005), is
the most abundant capsid protein and is positioned at the virion
surface, arranged into 240 homotrimeric structures interlinked
from neighboring monomers, thus providing structural support.
The fiber which engages the penton base at the capsid surface
projects away from the virion (San Martin and Burnett, 2003), is
highly variable in length, and is thought to be the major site
determining cell infectivity (reviewed in Nicklin et al., 2005). For
subgroup C adenoviruses, including Ad5, the globular fiber
knobpositionedat theendof the trimeric fiber shaft binds thecox-
sackievirus and adenovirus receptor (CAR), expressed in an ana-
tomically similar manner in mice and humans (Bergelson et al.,
1997; Tomko et al., 1997), whereas subgroup B adenovirusesCell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc. 397
utilize CD46, which is ubiquitously expressed in humans but lim-
ited to the testes in mice (Gaggar et al., 2003; Segerman et al.,
2003). Ad5 internalization is mediated by integrin engagement
with the penton base (Wickham et al., 1993). Extensive research
efforts have primarily focused on the fiber protein for analysis of
cell interactions in diverse gene therapy applications.
Following intravascular delivery, an important route of admin-
istration for many clinical applications, liver is the predominant
site of Ad5 sequestration with substantial hepatocyte transduc-
tion (Huard et al., 1995). Ad5 vectors engineered through muta-
genesis to lack CAR binding show identical liver transduction fol-
lowing intravascular injection in rodents and nonhuman primates
(Alemany andCuriel, 2001; Smith et al., 2003) indicating alternate
route(s) to gene transfer in vivo. A number of plasma proteins,
including coagulation factor IX (FIX) and complement binding
protein-4 (C4BP) were shown, using an ex vivo perfusion model,
to bind the Ad fiber knob and ‘‘bridge’’ the virus to alternate re-
ceptors in liver, thus potentially bypassing CAR (Shayakhmetov
et al., 2005). We showed using surface plasmon resonance
(SPR) that Ad5 bound directly to the vitamin K-dependent coag-
ulation factor X (FX) (Parker et al., 2006). In mice pretreated with
warfarin (to ablate functional levels of vitamin K-dependent co-
agulation factors) liver infection was reduced by several orders
of magnitude for both CAR-binding and CAR-binding-mutant
Ad5 vectors (Parker et al., 2006; Waddington et al., 2007), sug-
gesting an important function for host factors in liver targeting.
Injection of physiological levels of FX into warfarin-treated mice
prior to intravenous Ad5 injection fully restored liver gene transfer
(Parker et al., 2006; Waddington et al., 2007).
Based on this, Ad5, and potentially other adenoviruses, en-
gage host proteins for liver infection. Here, we characterize FX-
Ad5 binding in detail and reveal binding of FX to the Ad5 hexon,
not fiber. Binding occurs between the hexon hypervariable re-
gions (HVRs) and the FX Gla domain with cell binding dictated
by the FX serine protease domain. Thus, we provide evidence
for an unexpected function of the Ad5 hexon protein in cell infec-
tivity through recruitment of host FX. We also show that this
interaction extends to other (but not all) human adenovirus spe-
cies from multiple subgroups, indicating that it arose early in the
evolution of adenovirus as a pathogen.
RESULTS
The FX Gla Domain Is Required for Ad5 Binding
FX is a zymogen of a vitamin K-dependent serine protease with
a Gla (g-carboxylated glutamic acid)-EGF1 (epidermal growth
factor-like)-EGF2-SP (serine protease) domain structure (Fig-
ure 1A) that circulates in plasma at a concentration of 8 mg/ml.
FX is converted to its active serine protease by a single proteo-
lytic cleavage generating a two-chain disulphide-linked mole-
cule consisting of a light chain (LC; Gla-EGF1-EGF2) and a heavy
chain (HC; SP). There are three calcium ion binding sites in the FX
molecule—the Gla domain co-ordinates seven calcium ions, and
EGF1 and the SP domain each bind a single calcium ion. The FX-
Ad5 interaction is calcium dependent (Parker et al., 2006). We
sought to identify the domain responsible for Ad5 binding. To as-
certain whether the N-terminal Gla-EGF1 component of FX
bound Ad5 we assessed binding to full-length activated human398 Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc.FX (FXa; Gla-EGF1-EGF2-SP) and a human FXa mutant contain-
ing the C-terminal EGF2-SP domain (EGF2-SP FXa). The EGF2-
SP fragment failed to bind Ad5, which however did show efficient
binding to full-length FXa (Figure 1B). This suggests an absolute
requirement for Gla-EGF1 in Ad5 binding. This was confirmed
using a monoclonal antibody (HX-1) directed to the LC of FX
(Gla-EGF1-EGF2) that blocked the interaction of Ad5with human
FX (Figure 1C) and abolished human FX-mediated gene transfer
in vitro (for in vitro studies we used the CAR binding-ablated vi-
rus, AdKO1[Parker et al., 2006], since the use of this virusmimics
the CAR-independent liver gene transfer by Ad5 observed in vivo
[Parker et al., 2006; Waddington et al., 2007]) (Figure 1D). To
demonstrate the importance of the Gla domain in Ad5 binding
we analyzed the interaction of Ad5 with Gla domainless human
FX (FX-GD) by SPR. The effect of the FX Gla domain opposes
our earlier report (Parker et al., 2006) where we showed that
both FX and FX-GD evoked equivalent enhancements of in vitro
cell transduction mediated by Ad5. The FX-GD utilized was sub-
sequently shown to contain a significant quantity of full-length FX
bywestern blot analysis. For the present studywe therefore used
FX-GD additionally purified by affinity chromatography using an
anti-Gla antibody.Whereas Ad5 bound to full-length human FX in
a concentration-dependent manner, Ad5 failed to bind human
FX-GD (Figure 1E). In contrast HX-1 bound to both full-length
FX and FX-GD (data not shown). We attempted to produce puri-
fied Gla domain alone by enzymatic digestion of FX but insuffi-
cient quantities for analysis were obtained. To confirm the impor-
tance of this interaction in vivo, we pretreated mice with warfarin
to ablate circulating levels of functional vitamin K-dependent
zymogens and showed that human FX-GD failed to rescue
Ad5-mediated liver transduction (Figure 1F) despite achieving
‘‘normal’’ (8 mg/ml) physiological plasma concentrations of FX
(98%) and FX-GD (106%) as measured by human FX-specific
ELISA at 45 min post-infection with Ad5 (75 min post-injection
of zymogen). Hence, the FXGla domain is required for interaction
with Ad5.
FX Binds to the Ad5 Hexon
To determine the FX-binding site on Ad5, we initially focused
on the Ad5 fiber since it determines infectivity via CAR (Bergel-
son et al., 1997; Tomko et al., 1997). The interaction of Ad5
with FIX was identified through a knob-mediated interaction
(Shayakhmetov et al., 2005). To evaluate FX binding to Ad5 fiber,
we used a series of Ad5 vectors deleted of fiber knob alone, or
fiber knob and sequential fiber shaft deletions (Ad5-21R and
Ad5-7.5R; [Li et al., 2006), Figure 2A]), or a fully fiberless Ad5 par-
ticle (Ad5-DF; Von Seggern et al., 1999). Shaft mutants make use
of a fiber shaft trimerization motif for stable trimer formation in
the absence of knob (Li et al., 2006). All mutant adenoviruses
bound human FX efficiently as determined by SPR (Figure 2B).
We exposed cells to each adenovirus in the presence or absence
of physiological levels of human FX and quantified cell binding. In
each case the level of binding is low in the absence of FX but
strongly enhanced in its presence, even for fiberless particles
(Figure 2C). This suggests that FX binds an alternate Ad5 capsid
protein. Although the hexon is thought to act principally as
a structural capsid protein, based on its abundance and expo-
sure at the virion surface we next used SPR to determine
whether FX bound hexon. We observed a direct, calcium-
dependent high-affinity interaction between purified Ad5 hexon
and human FX (Figure 2D). The calculated association rate con-
stant (ka) and dissociation rate constant (kd) values of the FX for
immobilized hexon were 2.28 3 106 (1/Ms) and 4.5 3 103 (1/s)
giving an overall equilibrium dissociation constant (KD) of 1.953
109M. When FX was immobilized and hexon was injectedacross the biosensor, calculated ka and kd values were 2 3
105 (1/Ms) and 4.1 3 103 (1/s) giving an overall KD of 1.94 3
108M. To assess the affinity of FX for the intact virus Ad5 was
biotinylated and coupled to a streptavidin coated biosensor
chip. The calculated ka and kd values were 1.2 3 106 (1/Ms)
and 2.23 3 103 (1/s) giving an overall KD of 1.83 3 10
9M
(Figure S1 available online).Figure 1. Analysis of FX Binding to Ad5
(A) Domain structure of human FX. Green balls indicate calcium ions.
(B) Coagulation factors (FXa, EGF2-SP FXa) were covalently coupled to SA biosensor chip. Depicted are overlayed sensorgrams. Arrows indicate the start and
end of reagent injection. RU = response units.
(C) Antibody HX-1 directed against FX Gla-EGF1 was preinjected over the FX biocensor chip prior to Ad5 injection. HX-1 reduces FX-Ad5 binding (dRU). Arrows
indicate the start and end of reagent injection.
(D) HepG2 cells were exposed to AdKO1 in the presence of physiological FX levels. FXwas preincubated with antibody HX-1 or IgG isotype-matched control. Cell
transduction was quantified at 72 hr post-infection (**p < 0.001 versus control). Errors bars represent SEM.
(E) SPR analysis of Ad5 binding to FX and FX-GD that lacks the FX Gla domain. A subtracted sensorgram (FXI used as control for nonspecific binding) is shown.
Arrows indicate the start and end of reagent injection.
(F)MF-1mice were pretreatedwith control peanut oil or warfarin and injectedwith 43 1011 VP/mouse Ad5with or without preinjection of FX or FX-GD 30min prior
to virus injection. Quantitative ELISA for b-galactosidase shows levels in liver, spleen, and lung (*p = 0.03). Error bars represent SEM.Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc. 399
Electron Cryomicroscopy and Three-Dimensional
Reconstruction of Ad5 Bound to FX
To visualize the interaction between Ad5 and FX, three-dimen-
sional (3D) reconstructions were calculated from cryomicro-
graphs of both Ad5 and Ad5 complexed with FX. A total of 251
Ad5 and 305 FX-Ad5 virus particle images were used to compute
reconstructions at 26 A˚ and 23 A˚ resolution, respectively (Figures
3A and 3B). These maps clearly reveal that the principal point of
contact between Ad5 and FX occurs within the cup formed at the
center of each hexon trimer (Figures 3C–3F), supporting the FX-
hexon interaction seen by SPR. The structural information from
the FX component that extends from the capsid surface is noisy
and attenuated due to low occupancy (<50%) and incoherent
averaging with FX components bound to adjacent hexons
(Figure S2). The FX density at the binding site is significantly
stronger and shows symmetry congruent with the hexon trimer.
Such symmetry is not present in FX, suggesting that FX mole-
cules bind to one of three potential binding sites in each hexon
trimer, occluding the two remaining symmetry-related sites. FX400 Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc.density is then subject to three-fold averaging in the reconstruc-
tion. Modeling this interaction by fitting a high-resolution model
of FX (Venkateswarlu et al., 2002) to our reconstructions strongly
supports this interpretation (Figure S2). Moreover, SPR analysis
indicates a stoichiometery of binding of 205 FX molecules per
virus particle consistent with one FX molecule binding to each
hexon trimer. Interestingly, the region containing the FX-binding
site in hexon is characterized by the presence of HVRs (Rux and
Burnett, 2000). We investigated this by SPR analysis of an Ad5
mutant in which all HVRs have been replaced by those from
Ad48 (Ad5HVR48; [Roberts et al., 2006)(Figure 4A]). The remain-
der of the capsid structure is entirely derived from Ad5. Ad48 did
not bind FX (Figure 4B) and neither did the Ad5HVR48 mutant
(Figure 4B). Next, we determined the effect of HVR replacement
on infectivity. As Ad5HVR48 contains a wild-type Ad5 fiber with-
out a CAR-binding mutation, we used human cells with low CAR
levels (SKOV3 cells) for in vitro dissection of FX-mediated cell
binding and transduction mediated by Ad5, Ad5HVR48, and
Ad48. The HVR replacement resulted in a loss of FX-mediatedFigure 2. The Ad5 Hexon, Not Fiber, Binds to FX
(A) Representation of fibermutants used to assess binding of FX to Ad5. Ad5-21R contains 21 shaft repeats but no knob, Ad5-7.5R contains just 7.5 shaft repeats,
and Ad5-DF contains no fiber.
(B) Viruses were injected onto biosensor chips and binding to FX assessed. Subtracted sensorgrams (FX-FXI) are shown. Arrows indicate the start and end of
reagent injection.
(C) HepG2 cells exposed to each adenovirus in the presence or absence of physiological FX levels. Cell-bound adenovirus was quantified. Error bars represent
SEM.
(D) Purified Ad5 hexon protein was immobilized and binding to FXwas analyzed. Sensorgrams are shown for injections at seven different concentrations of FX (50
to 0.781 mg/ml in a two-fold dilution series). The analysis was performed in triplicate. Injection of EDTA regenerated the biosensor chip surface. Arrows indicate
the start and end of reagent injection.
enhancement of cell binding (Figure 4C) and transduction
(Figure 4D). An identical effect was obtained using the MDA-
MB-435 cell line (Figure S3). We next assessed liver gene trans-
fer in mice mediated by Ad5 and Ad5HVR48. Liver transduction,
measured at 3 doses 48 hr post-intravascular injection demon-
strated substantial reduction with Ad5HVR48 compared to Ad5
(Figure 4E). At the highest dose (5 3 1010 VP/mouse) an over
600-fold reduction in liver transgene expression was observed.
This contrasted with direct intramuscular injection, where Ad5-
and Ad5HVR48-driven transgene expression was not different
(Figure 4E). Thus, replacement of the Ad5 hexon HVRs with
those from Ad48 ablated FX binding, cell binding, and transduc-
tion in vitro and reduced liver transduction in vivo.
Liver Gene Transfer by the FX-Ad5 Complex
Blood coagulation proteases have evolved versatile and sensi-
tive mechanisms for controlling the specificity of protein sub-
strate recognition mediated by surface sites on the SP domain
that are physically separate from the active site residues (exo-
sites). The FX SP domain contains a heparin-binding exosite
(exosite II) (Rezaie, 2000). We had previously shown that FX-
enhanced transduction of cells required heparan sulfate proteo-
glycans (Parker et al., 2006, 2007) and therefore investigated
a role for this exosite in transduction of the FX-Ad5 complex.
We employed naturally occurring anticoagulants that bind FX
exosite II: nematode anticoagulant peptide-2 (NAPc2), an 85
amino acid polypeptide that is a potent FX-dependent inhibitorand binds human FXwith high affinity (KD = 7.283 10
11M; Table
S1; Figure 5A) (Murakami et al., 2007), and Ixolaris a 15.5 kDa
two-Kunitz domain protein isolated from tick salivary gland that
also binds human FX with high affinity (KD = 1.303 10
9M; Table
S1; Figure 5A) (Monteiro et al., 2005). SPR analysis revealed
high-affinity interaction between either NAPc2 and FX or Ixolaris
and human FX; however saturating amounts of either had no ef-
fect on Ad5 binding to human FX (Figure 5B). NAPc2 or Ixolaris
eliminated the ability of FX to enhance Ad5 transduction in vitro,
an effect observed at concentrations at or above the dissociation
constant (KD) for NAPc2-FX and Ixolaris-FX binding (Table S1;
Figure 5C). This effect was due to reduced cell-surface binding
of FX-Ad5 in the presence of inhibitor (Figure S4). In vivo, prein-
cubation of FX with NAPc2 or Ixolaris prior to injection into war-
farin-treatedmice led to a substantial reduction in FX liver rescue
(Figure 5D). Hence, binding of human FX to the Ad5 hexon
through the Gla domain leads to cell transduction in vivo medi-
ated through a heparin-binding exosite in the FX SP domain.
Pharmacological Blockade of Ad5 Hexon Binding
to FX Blocks Gene Transfer In Vivo
The treatment of mice with warfarin offers the potential to study
each vitamin K-dependent coagulation factor (FVII, FIX, FX, pro-
tein C) in isolation by complementation (Parker et al., 2006). Un-
der such conditions, FX is the only coagulation factor capable of
rescuing liver transduction mediated by Ad5 (Figure S5). The af-
finity of binding of each coagulation factor to purified Ad5 hexonFigure 3. Analysis of Ad5 Hexon Binding to FX by Cryoelecton Microscopy
(A and B) Three-dimensional reconstructions of uncomplexed Ad5 (A) and FX-Ad5 complex (B) surface contoured to include density above the mean plus one
standard deviation of total map density.
(C and D) Closeup view of an uncomplexed (C) and FX-complexed (D) hexon.
(E) Overlaid reconstructions of uncomplexed Ad5 (blue) and FX-Ad5 complex (purple). The scale bar represents 20 nm. The surface threshold level of the FX-Ad5
structure is raised to highlight the point of contact between FX and Ad5 hexon.
(F) Closeup view of FX-labeled hexon.Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc. 401
was quantified by SPR (Figure S6), again showing differential
kinetics for each coagulation factor and the predominant role
for FX in this interaction. It is important to ascertain the global402 Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc.importance of the FX-Ad5 interaction in the presence of all other
vitamin K-dependent zymogens under physiological conditions
in vivo. This is essential for further understanding of theFigure 4. Analysis of FX Binding and Adenovirus Infection in an HVR-Modified Ad5 Vector
(A) Sequence alignment of amino acids of Ad hexon HVRs from Ad5 and the Ad5HVR48mutant. White on black identical residues, black on gray similar residues,
and black on white nonidentical residues. The HVRs (1–7) are indicated.
(B) Ad5 binding to FX is abolished by replacement of Ad5 HVRs with those from Ad48, analyzed by SPR (subtracted FX-FXI sensorgrams). Arrows indicate the
start and end of reagent injection.
(C) SKOV3 cells were exposed to each adenovirus as indicated in the presence or absence of physiological FX levels for 1 hr at 4C. DNA was extracted and
cell-bound adenovirus quantified. Error bars represent SEM (p < 0.05 versus absence of FX).
(D) SKOV3 cells were exposed to each adenovirus as indicated in the presence or absence of physiological FX levels for 3 hr at 37C. Transgene expression was
quantified at 48 hr post-infection. Error bars represent SEM (p < 0.05 versus absence of FX).
(E) MF-1 mice were injected via the intravascular route with Ad5 or Ad5HVR48 at 53 109, 23 1010, or 53 1010 or VP/mouse and luciferase imaged at 48 hr and
quantified as photon flux. Intramuscular injections are shown as a comparison. Error bars represent SEM. *p = 0.00018, **p = 0.00002, ***p = 0.01368 versus Ad5.
importance of the interaction and how this may be used to de-
sign and implement inhibitors to block liver transduction by
Ad5. X-bp is a 29 kDa protein, isolated from Deinagkistrodon
acutus (the hundred pace snake), that binds with high affinity
to the Gla domain of human and murine FX (Atoda et al., 1998)
(Table S1). We thus utilized X-bp to define the effect of blockade
of the FX-Gla domain-Ad5 interaction on cell transduction in vitro
and in vivo. X-bp blocked the human FX-Ad5 interaction as evi-
denced by SPR, further demonstrating the importance of the Gla
domain in FX binding to Ad5 (Figure 6A). In vitro, preincubation of
human FX with X-bp at equimolar or higher concentrations prior
to addition of Ad5 to cells abolished the FX-mediated enhance-
ment in Ad5 transduction (Figure 6B). In vivo, X-bp when prein-
cubated with FX prior to injection blocked the ability of human
FX to rescue liver transduction by Ad5 in warfarinized mice
(Figure 6C). Importantly, preinjection of wild-type control (non-
warfarinised) mice with X-bp substantially reduced liver trans-
duction mediated by a subsequent injection of Ad5 (Figure 6D).
These findings were repeated in a second species (rat; Fig-
ure S7). Hence, based on our knowledge of the Ad5 hexon-FX
interaction we have identified an efficient and simple pharmaco-logical approach to block Ad5-mediated liver transduction
following intravascular delivery.
FX Binding to Other Human Ad Serotypes
The human adenovirus family is substantial with over 50 sero-
types, divided into subgroups A–F on the basis of hemagglutina-
tion, oncogenic properties, and DNA sequence identity. Many
adenoviruses are being exploited for application to treat human
diseases or for vaccination. A number of these approaches use
adenoviruses derived entirely from alternate serotypes (Abbink
et al., 2007; Lecollinet et al., 2006; Sakurai et al., 2006; Vogels
et al., 2003), althoughmany strategies simply use the Ad5 capsid
but exchange the Ad5 fiber for the fiber from an alternate sero-
type (also called pseudotyping) (Gaggar et al., 2003; Shayakh-
metov et al., 2000, 2002). Clearly, since FX binds the Ad5 hexon,
the pseudotyping strategy will result in viruses that still possess
FX-binding capacity and may possess FX-mediated infectivity
effects in vitro and in vivo (Parker et al., 2007; Waddington
et al., 2007). There are distinct advantages to using complete se-
rotypes that have rare pre-existing immunity in the human pop-
ulation (Abbink et al., 2007; Vogels et al., 2003) for clinicalFigure 5. Gene Transfer of Liver by the FX-Ad5 Complex Is Mediated through an Exosite in FX
(A) Ribbon diagram of FX (EGF2-SP; PDB: 1HCG) to show NAPc2 (purple), Ixolaris (green), and overlapping (red) amino acid residues within their FX binding sites
(Monteiro et al., 2005; Murakami et al., 2007).
(B) Subtracted SPR sensorgrams (FX-FXI) showing NAPc2 or Ixolaris binding to FXwithout inhibition of subsequent FX-Ad5 binding. Arrows indicate the start and
end of reagent injection.
(C) HepG2 cells were exposed to AdKO1 in the presence or absence of physiological FX ± NAPc2 or Ixolaris at increasing concentrations. Transduction was
quantified at 72 hr post-infection. Error bars represent SEM. ***p < 0.01 versus AdKO1 + FX.
(D) MF-1 mice were pretreated with control peanut oil or warfarin and injected with 4 3 1011 VP/mouse Ad5 with or without preinjection of FX alone or preincu-
bated with three-fold molar excess of either NAPc2 or Ixolaris. Quantitative ELISA for b-galactosidase levels in liver was performed 48 hr later and compared to
levels in the liver achieved by FX infusion alone. Error bars represent SEM. *p < 0.05 versus control.Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc. 403
application. The hexon protein is highly conserved between dif-
ferent serotypes (70%–80% sequence identity), but in the HVRs
there are distinct amino acid sequence profiles. Phylogenetic
analysis of the amino acid sequences of the HVRs identified
two distinct clades corresponding to the D subgroup and the
A, B, and C subgroups (Figure 7A) (Madisch et al., 2005). The ob-
served difference in amino acid sequences in the HVRs most
probably reflects the early divergence of subgroup D from A,
B, and C. We tested the ability of diverse human Ad serotypes
to bind FX by SPR (Figures 7A and 7B). Three phenotypes
were detected—adenoviruses that bind strongly, indicated by
++ or +++ (e.g., Ad5, Ad2, Ad50, Ad16); adenoviruses that
show weak FX binding, indicated by + (e.g., Ad35, Ad3); and ad-
enoviruses that do not bind FX at all, indicated in blue (e.g., Ad48,
Ad26) (Figures 7A and 7B). Viruses that do not bind FX all belong
to the D subgroup (Figure 7A). We next assessed whether bind-
ing to FX correlated with FX sensitivity in cell binding and trans-
duction in vitro and in vivo, focusing on Ad35 (weak binding) and
Ad26 (no binding), vectors that are in clinical development, and404 Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc.comparing this to Ad5 (strong binding). Kinetic analysis by SPR
for FX binding to Ad35 and Ad26 revealed for Ad35 a ka of 1.1
3 105 (1/Ms) and a kd of 5.7 3 103 (1/s), giving an overall KD
of 5.2 3 108M (Figure S8) and for Ad26 no detectable binding
even at 50 mg/ml FX (data not shown). The KD for Ad35 is, as ex-
pected, significantly weaker than the Ad5-FX interaction. In vitro,
Ad binding to and transduction of HepG2 cells was FX sensitive
for Ad5 but not for Ad35 and Ad26 (Figure 7C). For Ad35, injec-
tion into CD46 transgenic mice in either the presence or absence
of X-bp preinjection showed lung targeting (Figure 7D). For Ad26,
intravascular administration into mice revealed a complete lack
of liver transduction, either with or without preinjection of X-bp
(Figure 7D). In vivo analysis of Ad48, a second non-FX binding
serotype, also showed a lack of hepatic tropism (Figure 7D).
Taken together with the observations on Ad26, this indicates
that vectors derived from adenoviruses that show weak or no
binding to FX are not influenced by the FX pathway in vivo.
This has important implications for vector usage and engineering
strategies for gene therapy applications.Figure 6. Pharmacological Blockade of Ad5 Binding to FX by Snake Venom Protein X-bp Blocks Liver Transduction In Vivo
(A) Subtracted SPR sensorgram (FX-FXI) shows X-bp binding with high affinity (increase in RU following X-bp injection) and ablates subsequent FX-Ad5 binding
(no change in RU following Ad5 injection). Arrows indicate the start and end of reagent injection.
(B) HepG2 cells were exposed to AdKO1 in the presence of FX alone or FX preincubated with X-bp at different FX:X-bp molar ratios (as shown). ***p < 0.0001
versus no X-bp. Error bars represent SEM.
(C) MF-1 mice were pretreated with control peanut oil or warfarin and injected with 4 3 1011 VP/mouse Ad5 with or without preinjection of FX alone or preincu-
bated with three-fold molar excess of X-bp. *p = 0.006; **p = 0.0002. Error bars represent SEM.
(D) MF-1 mice (nonwarfarinized) were injected with X-bp 30 min prior to Ad5 injection. Forty-eight hours later liver gene transfer was quantified by ELISA
(bar graph) and visualized by staining for b-galactosidase (pictures). (**p = 0.0002). Error bars represent SEM.
DISCUSSION
We reveal an unexpected role for the Ad5 hexon protein for de-
fining virus infectivity in vivo. The complex of Ad5 with FX, medi-
ated through amolecular interaction between the FX Gla domain
and the hexon HVRs, is the major pathway leading to in vivo de-
livery of adenovirus to hepatocytes from the bloodstream. This is
supported by the over 150-fold reduction in liver transduction
mediated by Ad5 in mice preinjected with X-bp, a snake
venom-derived protein that blocks the molecular interaction of
FX Gla and Ad5 hexon. Moreover, the chimeric Ad5 vector
Ad5HVR48, which has only the HVRs of Ad48 swapped into
the Ad5 hexon, displays abolished FX binding activity by SPR
and in vitro assays as well as a substantial reduction in livergene transfer. It is important to remark that all other capsid com-
ponents in Ad5HVR48 are Ad5. The Ad5 fiber has no function in
FX binding as swapping Ad5 hexon HVRs for those from the non-
binding Ad48 abolishes FX binding capacity. This pathway has
fundamental implications for adenovirus biology and vector de-
sign for human gene therapy. Moreover, the role of the Ad hexon
protein in cellular infectivity provides important information
that may lead to the more effective development of safer gene
therapies.
Previously, we and others have reported that liver transduction
byCAR binding and CARbinding-mutated Ad5 vectors are equal
(reviewed in Nicklin et al., 2005; Waddington et al., 2007).
Clearly, fiber modifications have been shown to impact liver
transduction, including Ad5 vectors pseudotyped withFigure 7. FX Binding to Alternate Human Adenovirus Serotypes
(A) Phylogenetic tree based on alignment of hexon HVR amino acid sequences by ClustalW and visualized by Treeview (http://taxonomy.zoology.gla.ac.uk/rod/
treeview.html) showing FX binders (red) and nonbinders (blue) and strength of FX binding determined by SPR is indicated. Ad viruses not tested by SPR are shown
in black.
(B) Representative SPR sensograms depict human adenovirus serotypes that show strong (++ or +++), weak (+), or no binding to FX. Insets show expanded y axis
to show weak (Ad35) or not detectable binding (Ad26 and Ad48). Arrows indicate the start and end of injection.
(C) HepG2 cells were exposed to each adenovirus in the presence or absence of physiological FX. DNAwas extracted and cell-bound adenovirus quantified. Error
bars representSEM (*p<0.05 versus absenceof FX). Images show transgene (eGFP) expression following exposure for 3 hr at 37C in thepresence/absenceof FX.
(D) 53 1010 VP/mouse of Adwas injected either with or without 4.8mg/kg X-bp in CD46 transgenicmice (Oldstone et al., 1999) for Ad5 and Ad35 orMF-1mice for
Ad5, Ad26, or Ad48. At 48 hr post-infection, mice were subject to whole-body bioluminescence quantitation.Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc. 405
alternative fibers and Ad5 vectors devoid of the putative heparan
sulfate proteoglycan binding site in the fiber shaft (Koizumi et al.,
2006; Smith et al., 2003; reviewed in Nicklin et al., 2005). How-
ever, mutation at this site may confer fiber rigidity since vectors
possessing this mutation maintain the ability to bind cells but are
not able to mediate transduction (Bayo-Puxan et al., 2006; Kritz
et al., 2007). The lack of influence on liver transduction following
mutation of the fiber and/or penton proteins (Nicol et al., 2004;
Smith et al., 2003; Martin et al., 2003) suggests that these muta-
tions have not identified the natural mechanism for Ad5 localiza-
tion to hepatocytes following intravascular delivery. This is sup-
ported by the findings in our study as either pharmacological
intervention or mutation of the Ad5 hexon protein block Ad5-
FX interaction and liver transduction by Ad5 in vivo. Importantly,
Ad5HVR48 is still able to mediate transduction at a comparable
level to Ad5 following direct intramuscular injection, thus show-
ing that this virus still retains the ability to interact with its other
receptors in the appropriate in vivo setting. Together these find-
ings support the assertion that interaction between the Ad5
hexon and FX is the major pathway that the virus utilizes to
achieve localization to hepatocytes via the bloodstream. The
roles of other capsid proteins, including the fiber and penton,
in the entire liver transduction process relating to the FX-medi-
ated pathway will be important to ascertain. Transduction is
a complex series ofmechanisms including cell attachment, inter-
nalization, and nuclear trafficking, and our modeling suggested
projection of FX from the virion surface, thus potentially sterically
influencing fiber-mediated interactions. Importantly, liver trans-
duction is often a serious concern following local application of
adenovirus in vivo (Hiltunen et al., 2000), hence simultaneous
administration of an FX-Ad5 blocking agent may prevent such
occurrence, thus improving safety.
Blocking the hexon-FX interaction could be achieved by HVR
exchange as evidenced for Ad48 or by selective mutagenesis,
although careful analysis of full serotype tropism would be re-
quired, ideally focusing on serotypes that offer lower sero-prev-
alence with respect to pre-existing antibodies in the human pop-
ulation (Roberts et al., 2006). This would create adenoviruses
with both lower sero-prevalence in human populations and lack-
ing FX binding. Alternatively, mutagenesis strategies for Ad5
hexon, focusing on key interacting locales in HVRs to ablate
hexon-Ad5 interactions, will result in Ad5 mutants devoid of FX
binding.
This study has implications for vector design using pseudotyp-
ing strategies involving swapping of alternate (non-Ad5) fibers
onto the Ad5 capsid. Fibers derived from subgroup B Ads that
bind CD46 are of particular interest, as they mediate enhanced
Ad uptake into CD46-positive tissues, including tumors (Gaggar
et al., 2003; Sakurai et al., 2006; Tuve et al., 2006). Since we
show that Ad35 only weakly interacts with FX, it can be envis-
aged that development of full serotype Ad35 vectors may be
more preferential than using a fiber-pseudotyping strategy alone
since the Ad5 hexon will still bind FXwithin the context of a pseu-
dotyped virus. This is exemplified by our recent analysis of ade-
noviruses pseudotyped with fibers from subgroup D, all of which
showed direct binding to FX by SPR (in comparison to the diver-
gent data on the full subgroup D viruses presented here), result-
ing in enhanced FX-mediated cell-surface binding and transduc-406 Cell 132, 397–409, February 8, 2008 ª2008 Elsevier Inc.tion (Parker et al., 2007). Furthermore, in vivo targeting of Ad5/47
(a virus pseudotyped with the fiber from the subgroup D virus
Ad47) to the liver was sensitive to warfarin treatment, suggesting
that the binding of FX to Ad5 hexon leads to efficient liver target-
ing and is dominant over any fiber effects (Waddington et al.,
2007).
Taken together, this study identifies an unexpected function of
adenovirus hexon in mediating in vivo liver gene transfer by Ad5
through recruitment of host FX to the hexon HVR and cell binding
of the resulting complex through the FX serine protease. More-
over, this is an effect applicable to a number of alternate human
serotypes and has implications for adenovirus vector develop-
ment and safety for application to human gene therapy.
EXPERIMENTAL PROCEDURES
Materials
Purified blood coagulation factors (FX, FX-GD, protein C, and FXI) were
purchased from Haematologic Technologies Inc (Essex Junction, VT). Re-
combinant (r) FIX (BeneFIX) was from Wyeth (Philadelphia, PA, USA). rFVII
was sourced as described (Parker et al., 2006). rFX EGF2-SP was a kind gift
of Daniel Johnson (Cambridge, UK). FX-GD was prepared by chymotrypsin
digest of full-length FX (purchased from Haematologic Technologies Inc).
The FX-GD was further purified by removal of uncleaved full-length FX using
affinity chromatography with a monoclonal antibody to g-carboxy glutamic
acid residues (American Diagnostica, Stamford, CT, USA). rNAPc2 was
a kind gift of Dr G. Vlasuk (Corvas International, San Diego, CA, USA). Anti-
bodies were sourced as follows: HX-1 (Sigma, Poole, UK); monoclonal anti-
body 3570 against g-carboxyglutamic acid residues (American Diagnostica).
Ad5 hexon was purified from Ad5-infected cells according to the method of
Rux et al. (1999). Adenoviruseswere propagated in either PER.C6 cells (Vogels
et al., 2003) or in 293 cells (Parker et al., 2006). FX levels were determined using
a standard sandwich ELISA Asserachrom X:AG kit (Diagnostica Stago Inc.,
Parsipanny, NJ, USA). Plasma samples (1:9 ratio of blood: 3.8% sodium citrate
anticoagulant) were loaded in duplicate at both 1/50 and 1/200 dilutions. The
ELISA recognized both full-length FX and FX-GD with similar efficiency.
Surface Plasmon Resonance Analysis
SPR was performed using a Biacore T100 and a Biacore X (Biacore, Steven-
age, UK) (Parker et al., 2006). Coagulation factors were covalently immobilized
onto flowcells of CM5 biosensor chips by amine coupling according to the
manufacturer’s instructions. Virus in 10 mM HEPES (pH 7.4). 150 mM NaCl,
5 mM CaCl2, 0.005% Tween 20 was passed over the chip at 30 ml/min. Sen-
sorchips were regenerated between virus application by injection of 10 mM
HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20. FXa and
EGF2-serine protease FXa were biotinylated with biotin-FPRCK (Haemato-
logic Technologies Inc) at 25C overnight and then dialyzed. Ad5 was biotiny-
lated using the EZ-link sulfo-NHS-LC-biotinylation kit (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions. The biotinylated products
were coupled to streptavidin coated sensorchips (SA; Biacore) according
to the manufacturer’s instructions. Rmax was calculated from the immobilized
Ad5 (500 RU) using the formula: Rmax = MwFX / MwAd5 3 RI 3 S where s = 1.
To assess binding of Ad serotypes human (h) coagulation FXI and FX were co-
valently immobilized onto flowcells of a CM5 biosensor chip by amine coupling
(hFXI, 8496 RU; hFX, 6460 RU). Ad serotypes (100–0.79 3 1010 vp/ml,
8 two-fold serial dilutions were analyzed in duplicate) were passed over the
chip at 30 ml/min.
Kinetic Affinites of FX Inhibitors for Human and Mouse FX
Determined by SPR
Human (h) coagulation FXI (731 RU), FX (584 RU), mouse (m) FX (548 RU), and
purified Ad5 hexon (521 RU) were covalently immobilized onto flowcells
of a CM5 biosensor chip by amine coupling. X-bp, rNapc2, and Ixolaris
(10–0.078 mg/ml, 8 two-fold serial dilutions were analyzed in duplicate) or
coagulation factors (50–0.78 mg/ml, 7 two-fold serial dilutions analyzed in trip-
licate) were passed over the chip at 30 ml/min in 10mMHEPES (pH 7.4), 150mM
NaCl, 5mMCaCl2, 0.005%Tween 20. Sensorchips were regenerated by injec-
tion of glycine pH 2 for the inhibitors and 10mMHEPES (pH 7.4), 150mMNaCl,
3 mM EDTA, 0.005% Tween 20 for coagulation factors. Kinetic analysis was
performed using Biacore T100 evaluation software and fitted using a heteroge-
neous ligand model.
In Vitro Experiments
Human HepG2 cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM, Biowhittaker), supplemented with 2 mM L-glutamine (Invitrogen,
Paisley, UK) and 10% fetal calf serum (FCSPAA Laboratories, Yeovil, UK).
SKOV-3 andMDA-MB-435 cells were maintained in RPMI 1640media (Invitro-
gen) with 5% serum. For transgene expression, 23 104 cells/well were plated
into 96-well plates and transferred to serum-free media containing 8 mg/ml FX
(1 IU/ml; Cambridge Biosciences, Cambridge, UK). Virus was added at
1000 VP/cell for 3 hr at 37C. Cells were maintained at 37C until harvesting
at 72 hr. In experiments with NAPc2 and Ixolaris, FX was preincubated for
30 min. X-bp and FX (1 IU/ml) were mixed at varying molar ratios (10–0.001) for
30min. Expression of b-galactosidasewas quantified using TropixGalacto-Light
Plus (Applied Biosystems, Foster City, CA, USA) using aWallac VICTOR2 (Per-
kinElmer Life and Analytical Sciences, Boston, MA, USA) and recombinant
b-galactosidase as standard. Protein concentrations were quantified by bicin-
choninic acid assay (Perbio Science, Cramlington, UK). All data are expressed
as relative light units (RLU) per milligram of protein. Cells were imaged using an
Olympus BX40 microscope. Cell binding experiments were performed in 24-
well plates and in serum free media ± FX at 4C for 1 hr using 1000 VP/cell (un-
less otherwise stated). Viral and total genomic DNA were isolated using
a QIAamp DNA mini kit (QIAGEN, Crawley, UK), quantified by NanoDrop
(ND-1000 spectrophotometer [Labtech International, Ringmer, UK]). One hun-
dred nanograms of total DNA was subject to quantitative PCR analysis using
an ABI prism 7900HT Sequence detection system (Applied Biosystems, War-
rington, UK) using the Power SYBR Green PCR Master Mix as described
(Parker et al., 2006). Total Ad genomes were calculated using the SDS 2.3
software and using a standard curve of 102–107 Ad particles.
Electron Cryomicroscopy
Ad5 was incubated in the presence of an approximate three-fold excess of FX
overnight at 4C. Complexed and noncomplexed virus was prepared for elec-
tron cryomicroscopy as previously described (Adrian et al., 1984). Briefly, 5 ml
of virus was loaded onto a freshly glow-discharged Quantifoil holey carbon
support film (R2/2 Quantifoil Micro Tools GmbH, Jena, Germany), blotted,
and plunged into a bath of liquid nitrogen cooled ethane slush. Vitrified spec-
imens were imaged at low temperature in a JEOL 1200 EXII transmission elec-
tron microscope equipped with an Oxford instruments CT3500 cryo-transfer
stage. Low-dose focal pair images were recorded at 30,000 3 magnification
on Kodak SO163 film.
Three-Dimensional Image Reconstruction
Twenty and twenty-one focal pairs of micrographs were selected on the basis
of optimal ice-thickness for unlabeled and labeled virus, respectively. These
were digitized on a Nikon Super Coolscan 9000ED CCD scanner at 4000 dpi
resolution, corresponding to 2.18 A˚/pixel in the specimen. Scanned micro-
graphs were then converted to PIF (Purdue image format) and binned by a fac-
tor of three using the BSOFT image-processing package (Heymann, 2001),
giving a final raster step size of 6.54 A˚/pixel. X3D was used to select and cut
out individual particles; these were then processed to correct imaging artifacts
by determining the defocus of each micrograph and inverting successive os-
cillations of the contrast-transfer function using the CTFMIX program. Subse-
quently, full CTF correction was applied, merging defocus paired particle im-
ages (Conway and Steven, 1999). To calculate an initial reconstruction for
unlabeled Ad5, a common-lines approach was taken using a modified version
of the MRC icosahedral reconstruction suite of programs (Crowther et al.,
1970; Fuller et al., 1996). Following calculation of a preliminary reconstruction,
a modified version of the polar Fourier transform method (PFT2) was used to
determine and refine origins and orientations for each particle in both com-
plexed and noncomplexed data sets (Baker and Cheng, 1996; Bubeck et al.,2005). Resolution assessment for the final reconstructions was performed
by dividing each data set into equal halves. These were used to calculate
two independent reconstructions. A number of measures of agreement were
calculated for the two density maps, including the Fourier shell correlation
and spectral signal to noise ratio, using the BSOFT program bresolve. Recon-
structions were visualized using UCSF Chimera (Pettersen et al., 2004). The
Ad5-FX reconstruction is deposited in the EM database with accession code
EMD-1464.
In Vivo Methods
MF-1 outbred mice (Harlan, UK) or CD46 transgenic mice (Oldstone et al.,
1999) 25–30 g were used for all experiments. In some experiments, 5 mg/kg
warfarin suspended in peanut oil was injected subcutaneously 3 and 1 days
prior to Ad5 administration to ablate circulating levels of functional vitamin
K-dependent coagulation factors as described (Parker et al., 2006; Wadding-
ton et al., 2007). For NAPc2 and Ixolaris experiments, 400 mg/kg of NAPc2 or
0.78 mg/kg Ixolaris were pre-mixed with FX 30 min prior to intravenous injec-
tion of both. For X-bp studies we injected 4.8 mg/kg X-bp intravascularly in
warfarin-treated mice or into normal (nonwarfarinized) mice 30 min before in-
jection of adenovirus. For Ad5 versus Ad5HVR48 intravascular injection exper-
iments, mice received 200 ml intravenous clodronate liposomes (Van Rooijen
and Sanders, 1994) 24 hr before adenovirus. For intramuscular injections
1 3 1010 VP/mouse was injected into the tibialis anterior. Mice were subject
to whole-body bioluminescence quantitation (IVIS-50, Xenogen, USA) or were
sacrificed for analysis of tissue expression of b-galactosidase as described
(Waddington et al., 2007).
Statistical Analysis
In vitro experiments were performed in triplicate on at least three independent
occasions. In vivo experiments were performed with at least four animals per
group. Where necessary, data were normalized by logarithmic transformation.
Analysis was either by unpaired Student’s t test or for multiple comparisons,
analysis of variance and Tukey’s pairwise comparison using MINITAB
software.
Supplemental Data
Supplemental Data include one table and eight figures and can be found with
this article online at http://www.cell.com/cgi/content/full/132/3/397/DC1/.
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